If you think the stock market selloff has come to an end, Morgan Stanley has some bad news.

The S&P 500 is already down 16% year to date, but the Wall Street juggernaut believes the market has yet to hit a bottom.

“Our '22/'23/'24 base case estimates are now 3%/13%/14% below consensus, respectively,” a team of Morgan Stanley analysts led by Mike Wilson wrote in a note to investors earlier this fall. “In our base case, 2023 now marks a modest earnings contraction (-3% year-over-year growth), though we do not embed an economic recession in this scenario.”

“While acknowledging the poor performance in equities year-to-date, we do not think the bear market is over if our earnings forecasts are correct.”

Don't miss

• You could be the landlord of Walmart, Whole Foods and Kroger (and collect fat grocery store-anchored income on a quarterly basis)

• Want to invest your spare change but don't know where to start? There's an app for that

• Wine not? Here's why this real asset class is outperforming the S&P 500

The analysts expect the S&P 500 to fall to 3,400 by year-end. And if a recession hits the economy, they say the benchmark index could drop to 3,000.

Considering that the S&P 500 sits at around 3,992 right now, Morgan Stanley’s projection implies a further downside of 15% to 25%.

That doesn’t mean selling everything. The Wall Street firm still sees upside in quite a few companies. Here’s a look at three that it finds particularly attractive.

Eli Lilly (LLY)

This American pharmaceutical giant commands around $300 billion in market cap, with products marketed in 120 countries around the world.

Despite the market downturn this year, Eli Lilly is not a beaten-down stock.

In the first nine months of 2022, Eli Lilly’s revenue grew 5% year over year. Meanwhile, the company’s earnings per share improved 13% from a year ago.

Shares are actually up roughly 30% so far in 2022, and Morgan Stanley expects the trend to continue.

On Sept. 7, analyst Terence Flynn reiterated an “overweight” rating on Eli Lilly while raising his price target from $395 to $412.

Considering that Eli Lilly shares trade at around $349 apiece right now, the new price target implies a potential upside of 18%.

Welltower (WELL)

Welltower is in the real estate business.

The company doesn’t own fancy shopping malls or posh office buildings. Instead, it focuses on health care infrastructure and provides real estate capital to senior housing operators, post-acute care providers and health systems.

In Q3, Welltower’s normalized funds from operations — a key real estate metric — grew 5% year over year. Its same-store net operating income rose 7.2%.

Read more: Grow your hard-earned cash without the shaky stock market with these 3 easy alternatives

Health care is a recession-resistant sector, so health care-anchored real estate is typically in high demand.

The company also benefits from a major demographic tailwind: population aging.

Morgan Stanley analyst Ronald Kamdem notes that the population aged 75 and older is expected to grow by 4% annually through 2030, which could serve as a catalyst for Welltower’s business.

Kamdem has an “overweight” rating on the company and a price target of $90 — implying a potential upside of 26%.

Exxon Mobil (XOM)

Thanks to strong oil prices, energy stocks have turned out to be some of the best performers of the S&P 500 so far this year.

Exxon Mobil, for instance, is up 79% year to date — and that’s after a strong rally in 2021.

The oil-producing giant gushes profits and cash flow in this commodity price environment. Over the past 12 months, Exxon has generated $387 billion in revenue. Free cash flow has clocked in at a whopping $43.7 billion over the same time frame.

Solid financials allow the company to return cash to investors. Exxon pays quarterly dividends of 91 cents per share, translating to an annual yield of 3.2%.

Morgan Stanley analyst Devin McDermott has an “overweight” rating on Exxon and has raised his price target to $114 — which the company is just hovering under now.

What to read next

• You’re probably overpaying when you shop online — get this free tool before Black Friday

• These top 5 housing markets are expected to crash first — do you live in one of these fast-growing cities?

• Morgan Stanley: Prices for Rolex, Patek Philippe and Audemars Piguet watches will keep plunging due to a flood of supply — but these 3 real assets remain scarce and coveted

This article provides information only and should not be construed as advice. It is provided without warranty of any kind.